Sienna Biopharmaceuticals, Inc. (OTCMKTS:SNNAQ – Get Free Report) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 2,287 shares, a growth of 126.9% from the August 15th total of 1,008 shares. Based on an average trading volume of 9,208 shares, the days-to-cover ratio is presently 0.2 days.
Sienna Biopharmaceuticals Price Performance
Sienna Biopharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.00.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc (OTCMKTS: SNNAQ) is a specialty pharmaceutical company dedicated to the development, commercialization and acquisition of prescription therapies for dermatologic conditions. The company focuses on inflammatory skin disorders, hair loss and aesthetic applications by leveraging both in-licensing partnerships and targeted in-house research to bring novel and established treatments to market.
In 2020, Sienna launched ZILXI® (minocycline) foam 1% in the United States following FDA approval for the topical treatment of inflammatory lesions of rosacea.
Further Reading
- Five stocks we like better than Sienna Biopharmaceuticals
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
